B-Cell Pediatric ALL
Conditions
Keywords
pediatric cancer,pediatric acute lymphoblastic leukemia, lymphoblastic lymphoma, B-cell leukemia, ALL, moxetumomab pasudotox, CD22
Brief summary
The primary objective of this study is to evaluate the efficacy of moxetumomab pasudotox in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoblastic lymphoma.
Detailed description
This is a global, multicenter, open-label, single-arm Phase 2 study to evaluate the efficacy and safety of moxetumomab pasudotox monotherapy in pediatric participants with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma. Participants will be enrolled at sites in North America, Europe, and Australia. This is an approximate 35 month study.
Interventions
Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
Sponsors
MedImmune LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
- 1. Between the ages of greater or equal to (≥) 6 months and less than (\<) 18 years of age 2. Must have histologically proven B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoblastic lymphoma with marrow involvement 3. All participants (both ALL and participants with lymphoblastic lymphoma) must have M2 or M3 bone marrow classification 4. Disease status: a) Participants must have relapsed or refractory disease b) In the event of relapse after prior allogeneic hematopoietic stem cell transplant (HSCT), participants must be at least 3 months post-transplant and have no evidence of active graft-vs-host disease, and must have been off immunosuppression for at least 4 weeks, c) Must have resolution of the acute toxic effects to less than or equal to (≤) Grade 2 from prior chemotherapy before entry, in the opinion of the investigator 5. Participants with the following central nervous system (CNS) 1 or 2 status are eligible only in the absence of neurologic symptoms 6. Female participants of childbearing potential and post-pubertal male participants must use an approved method of contraception for the study.
Exclusion criteria
1. Concurrent enrollment in another clinical study for cancer treatment, unless the subject is in the follow-up period from a previous study. 2. Isolated testicular or CNS ALL 3. Participants with mixed-lineage leukemia (MLL) gene rearrangement 4. Inadequate Hepatic function 5. Inadequate Renal function 6. Radiologically-detected CNS lymphoma 7. Participants with clear laboratory or clinical evidence of disseminated intravascular coagulation (DIC) 8. Hyperleukocytosis or rapidly progressive disease that would compromise ability to complete study therapy 9. QT interval corrected using Fridericia's formula (QTcF) greater than or equal to a Grade 2, confirmed by 2 additional seperate electrocardiographs (ECG's) within 28 days prior to starting study drug. The initial screening ECG need not be repeated for confirmation if the QTcF interval is \<481 milliseconds. 10. Pregnant or breast-feeding females 11. Prior treatment with CAT-3888 (BL22), moxetumomab pasudotox, or any pseudomonas-exotoxin-containing compound 12. Prior treatment with any anticancer biologic therapy within 2 weeks prior to starting study drug, including but not limited to therapeutic monoclonal antibodies or antibody-drug conjugates 13. Systemic chemotherapy ≤ 2 weeks (6 weeks for nitrosoureas) and radiation therapy ≤ 3 weeks prior to starting study drug 14. Clinically significant ophthalmologic findings (evidence of retinal damage or injury) during the screening 15. Presence of a second invasive malignancy 16. Uncontrolled pulmonary infection, presence of pulmonary edema 17. Serum albumin \< 2 gram per deciliter (g/dL). Albumin infusions for correction of hypoalbuminemia are allowed, but cannot have administered within 7 days prior to start of study drug 18. Radioimmunotherapy within 2 years prior to study start of study drug 19. Participants with prior history of thrombotic microangiopathy or hemolytic uremic syndrome (HUS) 20. T-cell ALL or T-cell lymphoblastic lymphoma 21. Participants currently receiving high-dose estrogen therapy defined as \>0.625 milligram per day (mg/day) of an estrogen compound or within 2 weeks prior to starting study drug.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants With Composite Complete Response (CRc) | Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year | The CRc is defined as achieving complete response (CR), or CR with incomplete count recovery \[CRi\]) in participants with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma. Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts. The efficacy assessments were evaluated as per investigator assessment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Who Became Eligible to Receive an Stem Cell Transplant (SCT) After Treatment With Moxetumomab Pasudotox | Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year | The percentage of participants who became eligible for SCT after treatment with moxetumomab pasudotox were provided. The Clopper Pearson (Exact) 95% CI was calculated. |
| Overall Response Rate (ORR) | Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year | The ORR, defined as the percentage of participants with CRc or partial response (PR), was estimated; the Clopper Pearson (Exact) 95% CI was calculated. The CRc is defined as complete response (CR), or complete response with incomplete count recovery (CRi). Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts. |
| Time to Overall Response | Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year | Time to overall response was evaluated using the Kaplan-Meier method. |
| Best Overall Response (BOR) | Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year | The best overall response was calculated, based upon the disease assessments recorded during the study visits, and summarized with the number and percentage of participants for the following categories: CRc, PR, HA, SD, PD, and not evaluable. Overall best response is the best response observed for a participant during the study based on International Working Group (IWG) Response Criteria for malignant lymphoma. Complete response (CR) as per IWG is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is a minimum of 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses and no increase in the size of other nodes and in size of liver or spleen. Stable disease (SD) is when a participant fails to attain the criteria needed for a CR or PR, but does not fulfill those for PD. |
| Bone Marrow Blast Percentage Change | Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year | Change in bone marrow blast percentage from baseline was evaluated. If the percentage (%) blasts (at least 200 cells counted) is less than (\<) 5%, it is considered as M1, 5 to 25% considered as M2, greater than (\>) 25% considered as M3. Stages with the higher blasts relate to worse outcomes. |
| Time to Transplant to Receive an Stem Cell Transplant (SCT) After Treatment With Moxetumomab Pasudotox | Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year | The time to SCT was defined as the duration from the start of treatment with moxetumomab pasudotox until the date when the subject became eligible for SCT. The time to SCT was to be summarized using the Kaplan-Meier method, and was only to be evaluated for the subgroup of subjects who became eligible for SCT after treatment with moxetumomab pasudotox. |
| Percentage of Participants Who Were Neutropenic at Study Entry and Who Experienced Hematologic Activity (HA) | Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year | The percentage of participants who were neutropenic at study entry and experienced HA after treatment with moxetumomab pasudotox was evaluated. The Clopper Pearson (Exact) 95% CI was calculated. |
| Duration of Complete Response (DOCR) | Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year | DOCR was defined as the duration from the first documentation of CRc to the first documented disease progression.The CRc is defined as achieving complete response (CR), or CR with incomplete count recovery \[CRi\]) in participants with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma. Kaplan-Meier method was used for evaluation. |
| Duration of Overall Response (DOR) | Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year | DOR was to be defined as the duration from the first documentation of overall response to the first documented disease progression. Kaplan-Meier method was used for evaluation. |
| Progression-Free Survival (PFS) | Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year | PFS was measured from the start of treatment with moxetumomab pasudotox until the first documentation of disease progression or death due to any cause, whichever occurred first. Kaplan-Meier method was used for evaluation. |
| Overall Survival (OS) | Baseline to end of study or last contact date, up to 1 year | OS was determined as the time from the start of treatment with moxetumomab pasudotox until death due to any cause. For participants who were alive at the end of the study or lost to follow-up, OS was censored on the last date when the participant was known be alive. Kaplan-Meier method was used for evaluation. |
| Percentage of Participants With Minimal Residual Disease (MRD)-Negative CRc Rate | Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year | The MRD-negative CRc rate was defined as the percentage of participants who achieved CRc and became MRD-negative as determined by flow cytometry performed by a central analysis laboratory. The CRc is defined as complete response (CR), or complete response with incomplete count recovery (CRi). Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts. |
| Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Baseline up to 30 days after the last dose of study drug, up to 1 year | Laboratory tests were grouped according to hematology, serum chemistry, and urinalysis. Laboratory abnormalities with toxicity grades according to NCI CTCAE Version 4.03 were derived according to laboratory values and reported as treatment-emergent adverse events. |
| Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | Baseline up to 30 days after the last dose of study drug, up to 1 year | Participants were evaluated for ECG abnormalities. |
| Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) | Baseline up to 30 days after the last dose of study drug, up to 1 year | Participants who experienced vital signs abnormalities recorded as TEAEs were reported. |
| Number of Participants With Positive Anti-drug Antibody (ADA) and Neutralizing Antibodies (NAb) | Prior to the Start of Each Cycle for Cycles 1, 2, 3, and Subsequent Odd-Numbered Cycles, End of Treatment, and 30 Day Follow-up Visit, up to 1 year | Immunogenicity assessment included determination of antidrug (moxetumomab pasudotox) antibodies and neutralizing antidrug antibodies in serum samples. Titers and specificity were determined for NAb-positive participants. Specificity were observed in participants who had ADAs directed to the PE38 domain of moxetumomab pasudotox and increase in titers were observed in participants who tested ADA-positive at baseline. Moxetumomab pasudotox ADA-titer is a validated immunoassay, which determines titers or levels of ADAs present in ADA-positive samples. |
| Area Under the Plasma Concentration Time Curve From Time 0 to Infinity (AUC0-inf) After the First Dose of Cycle 1 | Pre-infusion, end of infusion (EOI); 1, 3, and 6 hours post-infusion of Day 1 of Cycle 1 | AUC (0-infinity) = Area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-infinity). It is obtained from AUC (0-t) plus AUC (tinfinity). It was calculated by extrapolating the concentrationtime curve from time zero to infinity using the linear/log trapezoidal rule. |
| Area Under the Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC0-last] After the First Dose of Cycle 1 | Pre-infusion, end of infusion (EOI); 1, 3, and 6 hours post-infusion at Day 1 of Cycle 1 | AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. AUC0-t is defined as AUC from time zero to the last data point above the lower limit of quantification. |
| Maximum Observed Drug Concentration in Plasma (Cmax) After the First Dose of Cycle 1 | Pre-infusion, end of infusion (EOI); 1, 3, and 6 hours post-infusion at Day 1 of Cycle 1 | Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. |
| Time to Reach Maximum Drug Concentration in Plasma (Tmax) After the First Dose of Cycle 1 | Pre-infusion, end of infusion (EOI); 1, 3, and 6 hours post-infusion at Day 1 of Cycle 1 | Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content. |
| Terminal Phase Elimination Half Life (t1/2) After the First Dose of Cycle 1 | Pre-infusion, end of infusion (EOI); 1, 3, and 6 hours post-infusion at Day 1 of Cycle 1 | Terminal phase elimination half-life is the time measured for the serum/plasma concentration to decrease by one half, calculated as natural logarithmic (log)-transformed (ln) value of 2 divided by elimination rate constant (lambda); that is \[ln(2)/lambda\]. Elimination rate constant (lambda) was estimated via linear regression of the time versus log concentration. |
| Systemic Clearance (CL) After the First Dose of Cycle 1 | Pre-infusion, end of infusion (EOI); 1, 3, and 6 hours post-infusion at Day 1 of Cycle 1 | CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC\[0-infinity\]). |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Baseline up to 30 days after the last dose of study drug, up to 1 year | Treatment-emergent adverse events (TEAEs), were defined as events present at baseline that worsened in intensity after administration of investigational product or events absent at baseline that emerged after administration of study drug. |
Countries
Australia, Canada, France, Italy, Netherlands, Spain, United Kingdom, United States
Participant flow
Pre-assignment details
A total of 37 participants were screened, of which 5 did not meet eligibility criteria and were considered as screen failures; the remaining 32 participants entered into the study and 30 participants were treated with moxetumomab pasudotox.
Participants by arm
| Arm | Count |
|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) Participants received 6 doses of moxetumomab pasudotox 40 mcg/kg intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy. | 32 |
| Total | 32 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 6 |
| Overall Study | Did not receive treatment | 2 |
| Overall Study | Initiation of alternative therapy | 2 |
| Overall Study | Investigator discretion | 1 |
| Overall Study | Other | 3 |
| Overall Study | Progressive disease | 17 |
Baseline characteristics
| Characteristic | Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) |
|---|---|
| Age, Continuous | 10.5 Years STANDARD_DEVIATION 3.9 |
| Sex: Female, Male Female | 13 Participants |
| Sex: Female, Male Male | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 30 / 30 |
| serious Total, serious adverse events | 16 / 30 |
Outcome results
Primary
Percentage of Participants With Composite Complete Response (CRc)
The CRc is defined as achieving complete response (CR), or CR with incomplete count recovery \[CRi\]) in participants with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma. Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts. The efficacy assessments were evaluated as per investigator assessment.
Time frame: Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year
Population: Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Percentage of Participants With Composite Complete Response (CRc) | 10.7 percentage of participants |
Secondary
Area Under the Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC0-last] After the First Dose of Cycle 1
AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. AUC0-t is defined as AUC from time zero to the last data point above the lower limit of quantification.
Time frame: Pre-infusion, end of infusion (EOI); 1, 3, and 6 hours post-infusion at Day 1 of Cycle 1
Population: Safety population who provided at least one measurable Pharmacokinetic concentration. Here, number of participants analysed, N included evaluable participants for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Area Under the Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration [AUC0-last] After the First Dose of Cycle 1 | 794 hour*nanogram per milliliter (hr*ng/mL) | Standard Deviation 239 |
Secondary
Area Under the Plasma Concentration Time Curve From Time 0 to Infinity (AUC0-inf) After the First Dose of Cycle 1
AUC (0-infinity) = Area under the serum concentration versus time curve from time zero (pre-dose) to extrapolated infinite time (0-infinity). It is obtained from AUC (0-t) plus AUC (tinfinity). It was calculated by extrapolating the concentrationtime curve from time zero to infinity using the linear/log trapezoidal rule.
Time frame: Pre-infusion, end of infusion (EOI); 1, 3, and 6 hours post-infusion of Day 1 of Cycle 1
Population: Safety population who provided at least one measurable Pharmacokinetic concentration. Here, number of participants analysed, N included evaluable participants for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Area Under the Plasma Concentration Time Curve From Time 0 to Infinity (AUC0-inf) After the First Dose of Cycle 1 | 1200 hour*nanogram per milliliter (hr*ng/mL) | Standard Deviation 224 |
Secondary
Best Overall Response (BOR)
The best overall response was calculated, based upon the disease assessments recorded during the study visits, and summarized with the number and percentage of participants for the following categories: CRc, PR, HA, SD, PD, and not evaluable. Overall best response is the best response observed for a participant during the study based on International Working Group (IWG) Response Criteria for malignant lymphoma. Complete response (CR) as per IWG is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. PR is a minimum of 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses and no increase in the size of other nodes and in size of liver or spleen. Stable disease (SD) is when a participant fails to attain the criteria needed for a CR or PR, but does not fulfill those for PD.
Time frame: Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year
Population: Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Best Overall Response (BOR) | Composite complete response | 10.7 percentage of participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Best Overall Response (BOR) | Partial response | 17.9 percentage of participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Best Overall Response (BOR) | Hematological activity | 7.1 percentage of participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Best Overall Response (BOR) | Stable disease | 21.4 percentage of participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Best Overall Response (BOR) | Progressive disease | 39.3 percentage of participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Best Overall Response (BOR) | No evaluation available | 3.6 percentage of participants |
Secondary
Bone Marrow Blast Percentage Change
Change in bone marrow blast percentage from baseline was evaluated. If the percentage (%) blasts (at least 200 cells counted) is less than (\<) 5%, it is considered as M1, 5 to 25% considered as M2, greater than (\>) 25% considered as M3. Stages with the higher blasts relate to worse outcomes.
Time frame: Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year
Population: The intent to treat (ITT) population included all participants who entered the study. Here, number of participants analysed, N included evaluable participants for this outcome measure.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Bone Marrow Blast Percentage Change | Baseline M1, post-baseline M1 | 0 percentage of participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Bone Marrow Blast Percentage Change | Baseline M1, post-baseline M2 | 0 percentage of participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Bone Marrow Blast Percentage Change | Baseline M1, post-baseline M3 | 3.8 percentage of participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Bone Marrow Blast Percentage Change | Baseline M2, post-baseline M1 | 0 percentage of participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Bone Marrow Blast Percentage Change | Baseline M2, post-baseline M2 | 0 percentage of participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Bone Marrow Blast Percentage Change | Baseline M2, post-baseline M3 | 7.7 percentage of participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Bone Marrow Blast Percentage Change | Baseline M3 post-baseline M1 | 3.8 percentage of participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Bone Marrow Blast Percentage Change | Baseline M3 post-baseline M2 | 11.5 percentage of participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Bone Marrow Blast Percentage Change | Baseline M3 post-baseline M3 | 73.1 percentage of participants |
Secondary
Duration of Complete Response (DOCR)
DOCR was defined as the duration from the first documentation of CRc to the first documented disease progression.The CRc is defined as achieving complete response (CR), or CR with incomplete count recovery \[CRi\]) in participants with relapsed or refractory B-cell ALL or B-cell lymphoblastic lymphoma. Kaplan-Meier method was used for evaluation.
Time frame: Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year
Population: Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment. Here, number of participants analysed, N included evaluable participants for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Duration of Complete Response (DOCR) | 1.97 months |
Secondary
Duration of Overall Response (DOR)
DOR was to be defined as the duration from the first documentation of overall response to the first documented disease progression. Kaplan-Meier method was used for evaluation.
Time frame: Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year
Population: Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Duration of Overall Response (DOR) | 0.95 months |
Secondary
Maximum Observed Drug Concentration in Plasma (Cmax) After the First Dose of Cycle 1
Cmax refers to the highest measured drug concentration which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample.
Time frame: Pre-infusion, end of infusion (EOI); 1, 3, and 6 hours post-infusion at Day 1 of Cycle 1
Population: Safety population who provided at least one measurable Pharmacokinetic concentration.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Maximum Observed Drug Concentration in Plasma (Cmax) After the First Dose of Cycle 1 | 457 nanogram per milliliter | Standard Deviation 128 |
Secondary
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE)
Laboratory tests were grouped according to hematology, serum chemistry, and urinalysis. Laboratory abnormalities with toxicity grades according to NCI CTCAE Version 4.03 were derived according to laboratory values and reported as treatment-emergent adverse events.
Time frame: Baseline up to 30 days after the last dose of study drug, up to 1 year
Population: Safety population includes all participants who received any amount of moxetumomab pasudotox.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Anaemia | 11 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Febrile neutropenia | 7 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Haemolytic uraemic syndrome | 4 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Thrombocytopenia | 1 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Platelet count decreased | 9 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Neutrophil count decreased | 6 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | White blood cell count decreased | 5 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Lymphocyte count decreased | 2 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | International normalised ratio increased | 1 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Alanine aminotransferase increased | 11 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Aspartate aminotransferase increased | 8 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Gamma-glutamyltransferase increased | 4 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Blood bilirubin increased | 2 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Blood creatinine increased | 2 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Blood lactate dehydrogenase increased | 2 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Bilirubin conjugated | 1 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Blood albumin decreased | 1 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Blood urea increased | 1 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Glucose tolerance increased | 1 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Hypoalbuminaemia | 6 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Hypocalcaemia | 6 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Hypokalaemia | 5 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Hyponatraemia | 5 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Hyperglycaemia | 4 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Hypophosphataemia | 3 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Hypermagnesaemia | 1 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Hypomagnesaemia | 1 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Hepatic function abnormal | 1 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAE) | Proteinuria | 1 participants |
Secondary
Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs)
Participants who experienced vital signs abnormalities recorded as TEAEs were reported.
Time frame: Baseline up to 30 days after the last dose of study drug, up to 1 year
Population: Safety population includes all participants who received any amount of moxetumomab pasudotox.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) | Pyrexia | 16 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) | Dyspnoea | 6 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) | Hypoxia | 4 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) | Hypertension | 8 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) | Hypotension | 4 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) | Weight decreased | 1 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) | Weight increased | 10 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) | Bradycardia | 7 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) | Sinus bradycardia | 1 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) | Sinus tachycardia | 3 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs) | Tachycardia | 3 participants |
Secondary
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Participants were evaluated for ECG abnormalities.
Time frame: Baseline up to 30 days after the last dose of study drug, up to 1 year
Population: Safety population includes all participants who received any amount of moxetumomab pasudotox.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities | 0 participants |
Secondary
Number of Participants With Positive Anti-drug Antibody (ADA) and Neutralizing Antibodies (NAb)
Immunogenicity assessment included determination of antidrug (moxetumomab pasudotox) antibodies and neutralizing antidrug antibodies in serum samples. Titers and specificity were determined for NAb-positive participants. Specificity were observed in participants who had ADAs directed to the PE38 domain of moxetumomab pasudotox and increase in titers were observed in participants who tested ADA-positive at baseline. Moxetumomab pasudotox ADA-titer is a validated immunoassay, which determines titers or levels of ADAs present in ADA-positive samples.
Time frame: Prior to the Start of Each Cycle for Cycles 1, 2, 3, and Subsequent Odd-Numbered Cycles, End of Treatment, and 30 Day Follow-up Visit, up to 1 year
Population: Safety population includes all participants who received any amount of moxetumomab pasudotox. Here, number of participants analysed, N included participants with at least one post-baseline sample.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Positive Anti-drug Antibody (ADA) and Neutralizing Antibodies (NAb) | Anti-drug Antibody (ADA) | 13 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Positive Anti-drug Antibody (ADA) and Neutralizing Antibodies (NAb) | Neutralizing Antibodies (NAb) | 13 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Positive Anti-drug Antibody (ADA) and Neutralizing Antibodies (NAb) | Increase in Titers | 3 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Positive Anti-drug Antibody (ADA) and Neutralizing Antibodies (NAb) | Specificity | 13 participants |
Secondary
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
Treatment-emergent adverse events (TEAEs), were defined as events present at baseline that worsened in intensity after administration of investigational product or events absent at baseline that emerged after administration of study drug.
Time frame: Baseline up to 30 days after the last dose of study drug, up to 1 year
Population: Safety population includes all participants who received any amount of moxetumomab pasudotox.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | TEAEs | 30 participants |
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | TESAEs | 16 participants |
Secondary
Overall Response Rate (ORR)
The ORR, defined as the percentage of participants with CRc or partial response (PR), was estimated; the Clopper Pearson (Exact) 95% CI was calculated. The CRc is defined as complete response (CR), or complete response with incomplete count recovery (CRi). Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts.
Time frame: Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year
Population: Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Overall Response Rate (ORR) | 28.6 percentage of participants |
Secondary
Overall Survival (OS)
OS was determined as the time from the start of treatment with moxetumomab pasudotox until death due to any cause. For participants who were alive at the end of the study or lost to follow-up, OS was censored on the last date when the participant was known be alive. Kaplan-Meier method was used for evaluation.
Time frame: Baseline to end of study or last contact date, up to 1 year
Population: Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Overall Survival (OS) | 3.6 months |
Secondary
Percentage of Participants Who Became Eligible to Receive an Stem Cell Transplant (SCT) After Treatment With Moxetumomab Pasudotox
The percentage of participants who became eligible for SCT after treatment with moxetumomab pasudotox were provided. The Clopper Pearson (Exact) 95% CI was calculated.
Time frame: Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year
Population: Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Percentage of Participants Who Became Eligible to Receive an Stem Cell Transplant (SCT) After Treatment With Moxetumomab Pasudotox | 0 percentage of participants |
Secondary
Percentage of Participants Who Were Neutropenic at Study Entry and Who Experienced Hematologic Activity (HA)
The percentage of participants who were neutropenic at study entry and experienced HA after treatment with moxetumomab pasudotox was evaluated. The Clopper Pearson (Exact) 95% CI was calculated.
Time frame: Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year
Population: Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Percentage of Participants Who Were Neutropenic at Study Entry and Who Experienced Hematologic Activity (HA) | 3.6 percentage of participants |
Secondary
Percentage of Participants With Minimal Residual Disease (MRD)-Negative CRc Rate
The MRD-negative CRc rate was defined as the percentage of participants who achieved CRc and became MRD-negative as determined by flow cytometry performed by a central analysis laboratory. The CRc is defined as complete response (CR), or complete response with incomplete count recovery (CRi). Complete response (CR) as per International Working Group (IWG) is complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy. Morphologic CR with incomplete blood count recovery (CRi) is defined as the above CR criteria without specified blood counts.
Time frame: Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year
Population: Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Percentage of Participants With Minimal Residual Disease (MRD)-Negative CRc Rate | 0 percentage of participants |
Secondary
Progression-Free Survival (PFS)
PFS was measured from the start of treatment with moxetumomab pasudotox until the first documentation of disease progression or death due to any cause, whichever occurred first. Kaplan-Meier method was used for evaluation.
Time frame: Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year
Population: Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Progression-Free Survival (PFS) | 1.4 months |
Secondary
Systemic Clearance (CL) After the First Dose of Cycle 1
CL is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma Area Under the Plasma Concentration-Time Curve From Time Zero to Infinite Time (AUC\[0-infinity\]).
Time frame: Pre-infusion, end of infusion (EOI); 1, 3, and 6 hours post-infusion at Day 1 of Cycle 1
Population: Safety population who provided at least one measurable Pharmacokinetic concentration. Here, number of participants analysed, N included evaluable participants for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Systemic Clearance (CL) After the First Dose of Cycle 1 | 34.4 milliliter per hour per kilogram | Full Range 5.72 |
Secondary
Terminal Phase Elimination Half Life (t1/2) After the First Dose of Cycle 1
Terminal phase elimination half-life is the time measured for the serum/plasma concentration to decrease by one half, calculated as natural logarithmic (log)-transformed (ln) value of 2 divided by elimination rate constant (lambda); that is \[ln(2)/lambda\]. Elimination rate constant (lambda) was estimated via linear regression of the time versus log concentration.
Time frame: Pre-infusion, end of infusion (EOI); 1, 3, and 6 hours post-infusion at Day 1 of Cycle 1
Population: Safety population who provided at least one measurable Pharmacokinetic concentration. Here, number of participants analysed, N included evaluable participants for this outcome measure.
| Arm | Measure | Value (MEDIAN) | Dispersion |
|---|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Terminal Phase Elimination Half Life (t1/2) After the First Dose of Cycle 1 | 1.02 hour | Full Range 0.213 |
Secondary
Time to Overall Response
Time to overall response was evaluated using the Kaplan-Meier method.
Time frame: Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year
Population: Efficacy evaluable population included all participants who received any amount of moxetumomab pasudotox and completed a baseline disease assessment and had at least one post-baseline disease assessment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Time to Overall Response | 0.66 months |
Secondary
Time to Reach Maximum Drug Concentration in Plasma (Tmax) After the First Dose of Cycle 1
Tmax refers to the time after dosing when a drug attains its highest measurable concentration (Cmax). It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content.
Time frame: Pre-infusion, end of infusion (EOI); 1, 3, and 6 hours post-infusion at Day 1 of Cycle 1
Population: Safety population who provided at least one measurable Pharmacokinetic concentration.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Moxetumomab Pasudotox 40 Microgram Per Kilogram (mcg/kg) | Time to Reach Maximum Drug Concentration in Plasma (Tmax) After the First Dose of Cycle 1 | 0.54 hour | Standard Deviation 0.05 |
Secondary
Time to Transplant to Receive an Stem Cell Transplant (SCT) After Treatment With Moxetumomab Pasudotox
The time to SCT was defined as the duration from the start of treatment with moxetumomab pasudotox until the date when the subject became eligible for SCT. The time to SCT was to be summarized using the Kaplan-Meier method, and was only to be evaluated for the subgroup of subjects who became eligible for SCT after treatment with moxetumomab pasudotox.
Time frame: Prior to Cycle 1, and prior to every cycle, at the end of treatment, at post-treatment follow-up visits, and at the end of the study, up to 1 year
Population: Efficacy population included participants who received moxetumomab pasudotox, completed a baseline disease assessment and had at least one post-baseline assessment. Since study was terminated prematurely, no participant received SCT after treatment with moxetumomab pasudotox, hence data were not collected for this Outcome measure.